All
Keytruda-Lenvima Combo Fails to Top Lenvima Alone in Patients With Unresectable Liver Cancer
August 9th 2022Treatment with Keytruda plus Lenvima did not best Lenvima alone as a first-line treatment option for a group of patients with liver cancer that could not be treated with surgery, according to recently announced study results from a phase 3 clinical trial.
Investigational Drug-Libtayo Combo Demonstrates Clinical Activity in Metastatic Prostate Cancer
August 8th 2022Treatment with an investigational drug plus with Libtayo showed encouraging anti-tumor activity in patients with advanced metastatic castration-resistant prostate cancer, according to preliminary data from an early-phase trial.
Few Patients With Breast Cancer Are Educated on Treatments' Affects on Sexual Health
August 8th 2022Although very few patients are informed about the effects that breast cancer treatments may have on their sexual health, many patients expressed wanting that information throughout all stages of their treatment, according to study findings.
Keytruda Plus Chemotherapy Is Not Superior to Chemotherapy Alone in Metastatic Prostate Cancer
August 8th 2022Keytruda plus chemotherapy failed to best the chemotherapy docetaxel alone in patients with metastatic castration-resistant prostate cancer, according to findings of a study of more than 1,000 patients.
FDA Approves Tablet Version of Calquence to Treat Multiple Blood Cancers
August 5th 2022The tablet version of Calquence, which was approved by the FDA for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia and relapsed/refractory mantle cell lymphoma, may be taken alongside other drugs to reduce gastric-related side effects.
Onivyde Fails to Improve Survival Over Chemotherapy in Second-Line Small Cell Lung Cancer
August 5th 2022Treatment with Onivyde failed to best the chemotherapy topotecan in improving overall survival in patients with small cell lung cancer whose disease failed to respond to platinum-based first-line treatment, according to findings from a primary analysis of the phase 3 RESILIENT trial.